Royalty Report: Drugs, Disease, Therapeutic – Collection: 203459

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Diagnostic
  • Drug Discovery
  • Assay
  • Test/Monitoring
  • Pharmaceuticals
  • Viral Infection
  • Antibiotic
  • HIV / AIDs
  • Molecular

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 203459

License Grant
Licensor grants an exclusive, even as to Licensor, license, with the right to sublicense, under Licensors interest in Collaboration Patents, and Collaboration Know-How, in each case solely to develop, make, have made, use, sell, have sold, offer for sale and import Products in the Field in the Territory; provided, however, that Licensor retains such rights under Collaboration Technology as are necessary to perform its obligations under the Research Program.

This agreement also includes Non-Exclusive Cross-Licenses where each Party hereby grants to the other Party a non-exclusive, royalty-free license, without the right to sub-license
(i) under such Partys interest in Collaboration Know-How for the manufacture or formulation of products other than Products, including 'cocktail' and other Combination Products; and
(ii) under such Partys interest in Collaboration Know-How, solely to conduct research in the HCV Field in the Territory.

License Property
Licensor has a research program for the discovery and optimization of nucleoside inhibitors of the NS5b polymerase in hepatitis C virus.

The Collaboration Compound shall mean a Nucleoside that satisfies the chemical and technical requirements set forth, and its Related Compounds and which
(a) is or was synthesized by or for Licensor on or before the Effective Date or during the Research Program Term; or
(b) is a Related Compound to a Collaboration Compound disclosed by Licensor to Licensee pursuant to Identification and Contribution of Collaboration Compounds and which is synthesized by or for Licensee after the Effective Date.

The Collaboration Compound Products shall mean any preparations in final form, bulk form or other form containing as an active pharmaceutical ingredient one or more Selected Compounds.

Field of Use
The Field shall mean all human and animal therapeutic, diagnostic, and prophylactic uses, including, without limitation, the treatment, prevention and prophylaxis of hepatitis C viral infections.

The HCV Field shall mean the treatment of chronic hepatitis C viral infections in humans.

The Collaboration Compound Products are for sale by prescription, over-the-counter or any other method, including without limitation any Combination Product.

IPSCIO Record ID: 239036

License Grant
This agreement is a research collaboration to apply Licensor Technology to Licensee HCV Compounds to develop the Collaboration Compounds.

For the License under Prior Technology and Collaboration Technology, Licensor grants to Merck an exclusive, even as to Licensor, license, with the right to sublicense, under Licensors interest in Prior Technology and Collaboration Technology solely to perform Licensees obligations under the Research Program during the Research Program Term and to develop, make, have made, use, sell, have sold, offer for sale and import Collaboration Compounds and Products in the Field in the Territory.

For the License under Licensor Technology, Licensor grants a non-exclusive license, with the right to sublicense as described below, under Licensors interest in Licensor Technology solely to perform Licensees obligations under the Research Program during the Research Program Term and to develop, make, have made, use, sell, have sold, offer for sale and import Collaboration Compounds and Products in the Field in the Territory.

For the Limited License Grant, Licensor grants, effective at the time such determination is made, to the extent Licensor is then legally able to do so, a non-exclusive license, including the right to sublicense as described below, under the HCV Claims solely to develop, make, have made, use, sell, offer for sale, have sold or import Collaboration Compound(s) and Product(s) in the Field in the Territory.

License Property
Licensor has developed Licensor Technology for the discovery and optimization of liver targeted compounds.

Licensor technology, know-how and patents relate to HepDirect Technology.

Field of Use
The Field shall mean the treatment of hepatitis C viral infections in humans.

IPSCIO Record ID: 291131

License Grant
Licensor hereby grants to Licensee an exclusive (even as to Licensor), royalty-bearing license in the Territory, with the right to sublicense through multiple tiers of sublicense, under Licensor’s interest in Collaboration Technology and Joint Technology, solely (A) to perform Licensee’s obligations under the Research Program during the Research Term and (B) to develop, make, have made, use, sell, have sold, offer for sale and import Development Candidates and Products in the Field during the Term; provided, however, that Licensor retains such rights under Licensors interest in Collaboration Technology and Joint Technology solely as are necessary to perform its obligations under the Research Program.

Licensor hereby grants to Licensee a non-exclusive, royalty-bearing license in the Territory, without the right to sublicense (except that Licensee may subcontract), under Licensor Technology Controlled by Licensor solely to perform Licensee’s obligations under the Research Program during the Research Term, and (B) Licensor hereby grants to Licensee a non-exclusive, royalty-bearing license in the Territory, with the right to sublicense as described below through multiple tiers of sublicense, under Licensor Technology Controlled by Licensor solely to develop, make, have made, use, sell, have sold, offer for sale and import Development Candidates and Products in the Field during the Term.

Licensor hereby grants to Licensee, a non-exclusive, royalty-bearing (included within the royalties as set forth) in license in the Territory, including the right to sublicense as described below through multiple tiers of sublicense, under such Specific Claims solely to develop, make, have made, use, sell, offer for sale, have sold or import such Development Candidate in the Field during the Term.

License Property
Product shall mean any preparation in final form containing a Development Candidate for sale by prescription, over-the-counter or any other method.

Joint Technology shall mean Joint Inventions and Joint Patents. Joint Patents shall mean Patents claiming any Joint Invention. Joint Invention shall mean any Invention conceived jointly by the Parties (or on their behalf) in the course of the Research Program during the Research Term; but excluding, in each case, Collaboration Technology, Licensee Technology and Licensor Technology.

Collaboration Technology shall mean Collaboration Know-How and Collaboration Patents.
Collaboration Patents shall mean Patents first filed after the Effective Date with claims or portions thereof, to the extent that they describe or claim a Collaboration Compound or a method of making or using a Collaboration Compound, where such Invention is conceived solely by a Party (or on its behalf) or jointly by the Parties (or on their behalf) in the course of the Research Program during the Research Term; provided that any Patent with the same disclosure as an Licensee Patent described in Agreement or a Licensor Patent described in Agreement, such as a renewal, division, continuation (in whole), or request for continued examination (RCE), reissue, reexamination or the like, will be included, as applicable.

Licensee Patents shall mean (a) Patents with claims or portions thereof, to the extent directed to any Invention that is an Licensee Nucleoside or Collaboration Compound or a method of making or using an Licensee Nucleoside or Collaboration Compound, where such Patents are Controlled by Licensee as of the Effective Date, (b) Patents with claims or portions thereof, to the extent directed to any Invention that is an Licensee Nucleoside or a method of making or using an Licensee Nucleoside, where such Invention first becomes Controlled by Licensee during the Research Term (provided that any such Patent with the same disclosure as a Patent described in subsection (a), such as a renewal, division, continuation (in whole), or request for continued examination (RCE), reissue, reexamination or the like, will be included in subsection (a) rather than subsection (b)) and (c) Patents with claims or portions thereof, to the extent directed to any Invention that is a Collaboration Compound or a method of making or using a Collaboration Compound, where such Invention first becomes Controlled by Licensee after the Research Term but prior to the First Commercial Sale of any Product that contains such Collaboration Compound.  Notwithstanding the foregoing, subsection (b), does not include any claims of such Patents or portions thereof to the extent directed to any such Invention that is a Collaboration Compound or a method of making or using a Collaboration Compound.  For purposes of clarity, Licensee Patents do not include Licensor Patents.  The Licensee Patents existing on the Effective Date are listed.
6,395,716 – .beta.-L-2-deoxy-nucleosides for the treatment of hepatitis B
6,569,837 – .beta.-L-2-deoxy pyrimidine nucleosides for the treatment of hepatitis B
6,914,054 – Methods and compositions for treating hepatitis C virus

Collaboration Compound shall mean a chemical entity that is synthesized solely by a Party or jointly by the Parties (or on behalf of a Party or the Parties) in the course of the Research Program during the Research Term that covalently incorporates HepDirect Technology and is converted into an Licensee Nucleoside (including any monophosphate, diphosphate or triphosphate thereof) in the body.

Combination Therapy shall mean a fixed dose product containing more than one (1) active pharmaceutical ingredient.  Separate products that are sold or promoted for sale together for co-administration shall not be considered a Combination Therapy.

Licensor Technology shall mean the Licesor Know-How and Licensor Patents.
Licensor Patents shall mean (a) Patents with claims or portions thereof, to the extent directed to any Invention that is HepDirect Technology or Collaboration Compound or a method of making or using HepDirect Technology or a Collaboration Compound, where such Patents are Controlled by Licensor as of the Effective Date, and (b) Patents with claims or portions thereof, to the extent directed to any Invention that is HepDirect Technology or a method of making or using HepDirect Technology, where such Invention first becomes Controlled by Licensor during the Research Term (provided that any such Patent with the same disclosure as a Patent described in subsection (a), such as a renewal, division, continuation (in whole), or request for continued examination (RCE), reissue, reexamination or the like, will be included in subsection (a) rather than subsection (b)).  Notwithstanding the foregoing, subsection (b) does not include any claims of such Patents or portions thereof to the extent directed to any such Invention that is a Collaboration Compound or a method of making or using a Collaboration Compound.  For purposes of clarity, Licensor Patents do not include Licensee Patents.  

Development Candidates for purposes of this Agreement means a designate one (1) or more Collaboration Compounds that possess the properties specified to the Research Plan.

HepDirect Technology shall mean (a) (i) any and all cyclic 1,3-propanyl esters or amides of phosphates, phosphoramidates and/or phosphonates that re activated by any P450 enzyme and/or (ii) any method of making or using any of the foregoing (this clause (a), “HepDirect Base Technology”); which (b) are the subject matter as originally claimed in the Licensor Core Patents as of the Effective Date or as claimed in any amendment filed in the Licensor Core Patents.

Field of Use
Field shall mean the treatment of chronic hepatitis C viral infections in humans.

IPSCIO Record ID: 279369

License Grant
Licensor grants an exclusive, even as to Licensor, license, with the right to sublicense, under Licensor Technology to Develop, make, have made, use, sell, have sold, offer for sale and import Compounds and Licensed Products in the Field in the Territory.

This agreement includes a non-exclusive grant back to Licensor.

License Property
Licensor has certain proprietary technology in compounds for the prevention and treatment of chronic hepatitis C infection.

The patents include Substituted Aryl Acylthioureas and Related Compounds Inhibitors of Viral Replication;
Heteroaryl Substituted Thioureas Inhibitors of Viral Replication;   Substituted Aryl Acylthioureas and Related Compounds Inhibitors of Viral Replication;  and, Substituted Arylthiourea Derivates Useful as Inhibitors of Viral Replication.

Compound means each of the following
—  inhibitors of HCV replication,  
—  any compound made pursuant to the Research Program with utility in the HCV Field or proven at a later date to have utility in the HCV Field; or,
—  any additional small molecules that are identified by either Party at any time prior to the end of the term of the Agreement, which can reasonably be demonstrated to inhibit HCV replication in replicon containing cells with a primary mechanism that results in abnormal processing of HCV proteins via HCV NS3 protease.

Field of Use
The Field means all human and animal therapeutic, diagnostic, and prophylactic uses, including, without limitation, the treatment, prevention and prophylaxis of hepatitis C viral infections.

HCV Field means the treatment of chronic hepatitis C viral infections in humans.

IPSCIO Record ID: 209534

License Grant
For Licensed Products,  Licensor grants the Swiss Licensee an exclusive, even as to Licensor, license under the Licensor Patent Rights and Know-How, with the right to grant sublicenses, to make, use, sell, offer for sale, import and export Licensed Products for all uses in the Territory.

For HCV Activity Compounds, Licensor grants an exclusive, even as to Licensor, license under the Licensor Patent Rights to make, use, offer for sale, import and export any HCV Activity Compounds solely within the Field in the Territory.

Licensor grants a non-exclusive license under any such patents to develop, make, have made, import, export, use, offer for sale and sell Licensed Products for all uses in the Territory.

For research, Licensor grants a non-exclusive license under its patents, trademarks and other intellectual property only to the extent necessary to carry out Licensees obligations and responsibilities under the Research Program and to develop and commercialize a Licensed Product.

Licensee, its Affiliates and sublicensees shall be free to use and to register in any trademark office worldwide any Trademark for use with Licensed Products they desire in their sole discretion.

License Property
The Licensed Product means anything containing or derived from a Candidate Compound.  The Candidate Compound means chemical entities designed or identified by Licensor as of the Effective Date or pursuant to the Research Program that are inhibitors of at least one (1) protease of the Hepatitis C virus.

HCV Activity Compounds means Candidate Compounds, other than Licensed Products or Back-Up Compounds, or Non-Collaboration Compounds meeting the HCV Activity Criteria set forth.

The patents are those filed to protect Licensor Inventions or interest in Joint Inventions, or otherwise filed to protect either a transition state-based inhibitor of the NS3 protease of the Hepatitis C virus existing within Licensor Know-How as of the Effective Date or an inhibitor of the Hepatitis C viral proteases within Licensor KnowHow arising from the Research Program.

Field of Use
This agreement is for the treatment or prevention of Hepatitis C infections in humans and/or animals.

IPSCIO Record ID: 148361

License Grant
Licensor grants to Licensee
– the sole and exclusive worldwide right and license, with no right to sublicense under both the Licensors Technology and interest in any Joint Technology,  to use the Licensor Transporters for the identification   and/or development  of Lead Compounds and Collaboration Products in the Field of Use;

– the sole and exclusive worldwide right and license,  with the right to sublicense to Affiliates of Licensee and/or one or more Third Parties,  under both the Licensor Technology and interest in any Joint Technology,  to make, have made, use, import,  market,  offer for sale and sell Lead Compounds and Collaboration Products in the Field of Use;

– during the term of the Research Program, the sole and exclusive right and license, with no right to sublicense, under both the Licensor Ancillary Transporter Technology and interest in any Joint Technology,  to use the Licensor Ancillary Transporters  for the sole purpose of conducting selectivity testing of Lead Compounds and Collaboration Products;

– after the term of the Research Program, a non-exclusive right and license,  with no right to sublicense,  under the Licensor Ancillary Transporter Technology to use the Licensor  Ancillary Transporters for the sole purpose of conducting selectivity testing of Lead Compounds and Collaboration Products;

– during the term of this Agreement, a nonexclusive right and license, with no right to sublicense, to use all data and information generated by or on behalf of Licensor in the conduct of the Research  Program,  including data relating to Hits in the Licensor Proprietary Chemical Library, but only as shall be reasonably  necessary for Licensee to conduct research to identify and develop Lead Compounds and   Collaboration Products,  provided,  however,  that such license shall become sole and exclusive when a  Compound is designated a Lead Compound in accordance  with Article Six and shall revert to a non-exclusive  license  upon  determination  of  the  Steering Committee or  Licensee  that such Lead  Compound will not become a Collaboration Product;

– during the term of this Agreement, an exclusive right and license,  with the right to sublicense,  to use all data and information generated by or on behalf of Licensor in the conduct of the  Research Program  relating to Lead Compounds and/or Collaboration Products in the Licensor Proprietary Chemical Library,  but only as shall be reasonably necessary for Licensee to conduct research to identify and develop Lead Compounds and Collaboration Products; and

– during the term of this Agreement,  a non-exclusive right and license,  with no right to sublicense, to use the Licensor Materials but only to the extent that such right and license shall be necessary for Licensee to identify and develop Lead Compounds and Collaboration Products.

License Property
Licensor is the owner or licensee of certain patent rights relating to human glutamate transporters.

Glutamate transporters are a family of neurotransmitter transporter proteins that move glutamate – the principal excitatory neurotransmitter – across a membrane.

Licensor Transporters mean EAAT-2 and EAAT-3  protein of amino-acid compositions.

Field of Use
The field means all therapeutic, prophylactic and diagnostic uses.

IPSCIO Record ID: 222558

License Grant
For the Compounds and Products, Licensor grants an exclusive license under the Licensor Technology and Licensors interest in the Collaboration Technology, exclusive even as to Licensor and its Affiliates, to make, have made, use, sell, offer to sell, import and export Agreement Products in the Territory. It is understood that such licenses shall include the right to conduct drug research and development, and the exclusive right to discover, develop, make, have made and use Agreement Compounds, during the term of this Agreement.

For the Collaboration Target-Specific Technology, Licensor grants an exclusive license, exclusive even as to  Licensor and its Affiliates, under all of Licensors interest in the Collaboration Target-Specific Technology for any and all purposes in the Territory, including the right to grant sublicenses.

For the Collaboration Platform Technology, upon conclusion of the Collaboration Term, the Parties each  grant, to the other a co-exclusive license under their respective interests in the Collaboration Platform Technology in the Territory, as follows  the Parties may each use such Collaboration Platform Technology for any and all internal uses, including without limitation, in collaboration with Third Parties for drug discovery.

For the Columbia Sublicense, Licensor grants a non-exclusive sublicense, without the right to sublicense, under the Columbia License, to make, have made, use, offer to sell, sell, import and export Agreement Products in the Territory, including, without limitation, the right to decode Library Compounds.

License Property
Licensor has developed proprietary technologies relating to the design and preparation of encoded compound libraries based upon combinatorial chemistry.  'Licensor Technology' shall mean Existing Licensor Patent Rights, Existing Licensor Know-How, and Licensor Improvements (with some exceptions).

Product means any Agreement Product or Licensees Product.

Agreement Product shall mean any product containing an Agreement Compound, including, without limitation, products for the therapeutic or prophylactic treatment or prevention of diseases and conditions in human beings or animals.

Licensees Product shall mean any product for the therapeutic or prophylactic treatment or prevention of diseases and conditions in human beings containing a Licensee Compound, provided such Licensee Product is not a Combination Product containing both a Licensee Compound and an Agreement Compound.

Active Compound shall mean a Library Compound that demonstrates activity against a specific Target, which Library Compound was found to have such activity at a concentration set forth in the applicable Collaboration Research Plan during screening of one or more Libraries by Licensor in the conduct of the Collaboration or was found to have such activity during screening by or on behalf of Licensee.

Licensor's combinatorial chemistry technology as an important component in our ongoing efforts to accelerate the drug discovery process and to identify lead compounds for development as new therapeutic entities.'

Field of Use
This agreement field relates to assays, compound screening methods and biological research tools used to design, prepare and screen compound libraries against Licensees biological targets.

IPSCIO Record ID: 243481

License Grant
The Licensor of the United Kingdom and Licensee wish to collaborate on the discovery and development of Hepatitis C inhibitors which act through the viral replicase enzyme.

The United Kingdom Licensor grants an exclusive license, under the Licensor Patents and under Licensor Know-How, to make, have made, use, import, offer to sell, sell and have sold Products in the Territory. Licensor also grants the right to sublicense.

This agreement also includes a non-exclusive grant back to the Licensor.

License Property
The Licensors library consists of Millions of compounds for potential use in high throughput screening are available for purchase from commercial suppliers.  Licensor has used state-of-the-art molecular design software to analyse these commercial compound libraries both for chemical diversity and drug potential, which are critical parameters in developing novel lead compounds. On the basis of these analyses, Licensor has purchased a unique set of chemically diverse, drug-like molecules. Licensors library has also been selected to avoid poor chemical starting points for drug design. The Licensor Library currently contains approximately 50,000 compounds and all of these will be evaluated in the hepC polymerase primary assay.  Compounds which demonstrate activity in the primary assay, will be defined as selected compounds. All other compounds will remain proprietary to Licensor.

Licensee sourced compounds mean compounds supplied by Licensee to Licensor for the purpose of screening by Licensor pursuant to the Research Program in the HCV Replicase Assay.

Field of Use
The primary assay to be used in the research program will determine the inhibitory effects of compounds from Licensor or Licensee libraries on a truncated form of the Hepatitis C RNA polymerase.

The Parties wish to collaborate on the discovery and development of Hepatitis C inhibitors which act through the viral replicase enzyme.

IPSCIO Record ID: 203549

License Grant
For the technology, Licensor grants the Licensee of Bermuda, an exclusive, even as to Licensor, worldwide, sub-licensable license, under the Licensors Technology, to develop, make, have made, use, sell, have sold, offer for sale and import the Licensors Compounds and Products in the Primary Fields; and to develop, make and have made the Licensors Compounds and Products in the ID Field, but without any right to sell or commercialize in the ID Field. Licensee may sublicense the rights granted.

Each Party hereby grants to the other Party a non-exclusive, non-sublicensable (except to Affiliates) license to its Patent Rights and Know-How solely to the extent necessary to permit such other Party to perform its responsibilities relating to the Anadys Compound or Product under the Development Plan during the term of this Agreement.

License Property
The product is any product incorporating or comprising the Lead Compound or any other Licensors Compound in finished dosage pharmaceutical form, including, in each case, all formulations and modes of administration thereof, the development, manufacture, sale or use of such Lead Compound or other Licensor Compound would, but for the license granted hereunder, infringe the Licensor Patent Rights or incorporates or embodies Licensor Know-How.

The licensing and co-development agreement is for the development and potential commercialization of ANA975 and potentially additional Toll-Like Receptor (“TLR7”) oral prodrugs for chronic hepatitis C virus (“HCV”) and hepatitis B virus (“HBV”) infections, as well as other potential infectious disease indications.

ANA975, a 5-amino-3-ß -D-ribofuranosyl-3H-thiazolo[4,5-d]pyrimidin-2-one derivative, was synthesized in the search of an oral prodrug of isatoribine, a small molecule toll-like receptor 7 (TLR-7) agonist.

Toll-like receptor 7, also known as TLR7, is a protein that in humans is encoded by the TLR7 gene.

Field of Use
The primary field is the HCV Field and HBV Field. Primary field shall mean either the HCV Field or the HBV Field, as applicable.

ID field means the treatment, diagnosis or prevention of infectious diseases outside of the Primary Fields.

HBV field means the treatment, diagnosis or prevention of hepatitis B virus (HBV).
HCV field means the treatment, diagnosis or prevention of hepatitis C virus (HCV).

IPSCIO Record ID: 280326

License Grant
The parties wish to enter into a collaboration employing Licensees medicinal chemistry, analytical chemistry and primary biology capabilities and Licensors chemistry, in vitro biology, and in vivo biology capabilities, in order to develop and commercialize pharmaceutical compounds subject to and in accordance with the terms and conditions of this Agreement (the “Collaboration”).

License to Commercialize Collaboration Compounds – With respect to all Collaboration Compounds for which Licensee has received Licensors approval to develop and commercialize, Licensor grants to Licensee a worldwide, exclusive license, with the right to sublicense, under the Licensor IP and Licensor’s interest in the Collaboration IP, to make, have made, use, sell, offer to sell and import Collaboration Compounds, and/or Collaboration Products based on such Collaboration Compounds, for any and all uses and indications in the Licensee Field.

License to Compounds (Other than Collaboration Compounds) Derived from Licensee Compounds –  Licensor grants to Licensee a worldwide, perpetual, exclusive, royalty-free license, with the right to sublicense, under Licensors interest in the Collaboration IP, to exploit for any and all purposes all compounds (other than Collaboration Compounds) derived, directly or indirectly, from Licensee Compounds.

Research Licenses – The Parties hereby grant each other non-exclusive, worldwide, royalty-free research licenses, without the right to sublicense, under their respective interests in the Licensee IP, Licensor IP and Collaboration IP, in order for each Party to perform its research obligations pursuant to Research Plans during the Collaboration Term.

License Property
Collaboration Compound shall mean a Licensee Compound or a Non-Exclusive Compound or a compound that is derived, directly or indirectly, from a Licensor Compound, Licensor Compound, or Non-Exclusive Compound; in each case, that modulates the biological activity of a Collaboration Target at a level of potency to be established by the JRC.  A compound shall be deemed to have been derived directly from another compound if it (i) is the result of a chemical modification made to such a compound, (ii) is otherwise obtained from a chemical synthesis program based on one or more such compounds, (iii) is based on proprietary structure-activity data obtained from the testing of one or more such compounds, or (iv) is specifically or generically within the scope of one or more claims of any patent application or patent filed by Licensee or Licensor or their Affiliates to protect any compound in category (i), (ii) or (iii) above.  A compound shall be deemed to have been derived indirectly from another compound if it is the result of a series of iterations of any or all of (i) through (iv) above.  For purposes of clarity, any compound synthesized in the course of the Collaboration and based on a Licensor Compound, Licensee Compound, or Non-Exclusive Compound which is active against a Collaboration Target at the level of potency established by the JRC shall be deemed a Collaboration Compound.

Licensee IP shall mean Licensee Patents and Licensee Know-how.  Licensee IP shall not include any intellectual property owned or licensed by Licensee or its Affiliates relating to the ECLiPSâ„¢ technology (i.e., the creation or use of encoded combinatorial libraries or any tag and/or marker compounds).

Field of Use
Licensee Field shall mean, with respect to each Collaboration Compound for which Licensee has received approval to develop pursuant, all human and animal disorders and diseases treated by modulation of a Collaboration Target by such Collaboration Compound.

Licensor Field shall mean, with respect to each Collaboration Compound, all human and animal disorders and diseases treated by modulation of a Collaboration Target by such Collaboration Compound.

The primary objective of the alliance is to identify active molecules and bring them forward to clinical proof of concept, yielding novel candidates for drug development in various therapeutic areas.

IPSCIO Record ID: 245901

License Grant
Licensor hereby grants to the Belgium Licensee an exclusive royalty-bearing right and license, with the right to grant sublicenses, under the Licensor Intellectual Property and Licensors interest in the Collaboration Intellectual Property, to research, develop, make, have made, import, export, use, sell, offer for sale, have sold, distribute, promote, commercialize and otherwise exploit Collaboration Products in the Field in the Territoty; provided, however, that Licensor retains the right under the Licensor Intellectual Property and the Collaboration Intellectual Property to perform Licensors obligations under this Agreement, including conducting the activities set forth in the Joint Plan and Budget.
License Property
Collaboration Product means a Compound, or a pharmaceutical product containing a Compound which product is in any form or formulation or combination, delivery or production system ( e.g., cell lines that produce the protein or peptide therapeutic), or package configuration. For clarity and purposes of this Agreement, antibodies, antibody fragments, chemical compounds, antisense therapeutics, RNA and DNA therapeutics are not Collaboration Products, and 'Collaboration Product' shall not include Licensor Compositions, where 'Licensor Composition' means any active pharmaceutical ingredient ( other than a Compound) whose composition of matter, or method of manufacture or use, is claimed in or embodies any Patent Rights or Know-How solely or jointly with a Third Party owned or controlled by Licensor or any of its Affiliates which was discovered by Licensor or any of its Affiliates outside of the Research Collaboration.

Compound means any native, mutated, or chimeric protein or peptide therapeutic that directly modulates a Target (a 'Target Modulator') and was identified, and such modulation confirmed, by Licensor or Licensee in the performance of the Research Collaboration. For clarity and purposes of this Agreement, antibodies, antibody fragments, chemical compounds, antisense therapeutics, RNA and DNA therapeutics are not Compounds or Target Modulators.

Collaboration Intellectual Property means Collaboration Know-How and Collaboration Patent Rights.

Field of Use
Licensee will utilize Licensor’s proprietary AMP-Rx protein design technology to create a novel therapeutic of Licensee’ selection optimized for improved pharmaceutical characteristics and therapeutic benefits for the treatment of diabetic eye diseases.

IPSCIO Record ID: 27438

License Grant
Licensor hereby grants to Licensee (a) the exclusive worldwide right and license, without the right to grant sublicenses to use the Licensor's Technology, the Licensor's Chemical Library, and the Collaboration Targets only to the extent necessary for Licensee to exercise its rights and perform its obligations under the Research Program and to exercise its rights and perform its obligations during the Screening Phase Tail.
License Property
Licensor is the owner of certain patent rights and know-how relating to the hepatitis C virus and compounds and methods for treating humans infected with the hepatitis C virus.

'HCV' shall mean the hepatitis C virus.

Field of Use
Field shall mean the therapeutic and/or prophylactic treatment of the effects of HCV on humans.

IPSCIO Record ID: 203480

License Grant
Pursuant to the terms of this Agreement, the Parties wish to terminate the Multi-Project Collaboration Agreement and enter into this Agreement to pursue research, development and marketing of products based on specific focused areas.

The Parties are establishing a collaborative effort to perform research and develop and market products for the prevention, diagnosis, and treatment of skeletal muscle disorders.

For the Termination of the Multi-Project Collaboration Agreement and Overview and Management of Collaboration portion of this Collaboration agreement, the Multi-Project Collaboration Agreement is hereby terminated, and contrary to the Multi-Project Collaboration Agreement, Licensee shall own all Inventions discovered by employees of Licensee as part of any Licensee Retained Project and having no utility in the Field as of the Effective Date.

Licensor grants an exclusive License under its Patents and Know-how whether solely owned by Licensor or jointly owned with Licensee which were conceived and reduced to practice in connection with any Licensee Retained Project at any time through December 31, 2000 and as of December 31, 2000 have no known use in the Field or in any Licensor Retained Project to make, have made, use, import, offer for sale and sell any products for the prevention, diagnosis, or treatment of any diseases or disorders in humans or animals in connection with any Licensee Retained Project.

Licensor grants a non-exclusive License under its Patents and Know-how which were conceived and reduced to practice in connection with any Licensee Retained Project at any time through December 31, 2000 and as of December 31, 2000 have known use in the Field or in any Licensor Retained Project, to make, have made, use, import, offer for sale and sell any products for the prevention, diagnosis, or treatment of any disease or disorder in humans or animals in connection with any Licensee Retained Project.

Licensor grants a non-exclusive License under its Patents and Know-how conceived and reduced to practice in connection with any Mutual Retained Project at any time through December 31, 2000, to make, have made, use, import, offer for sale and sell any products for the prevention, diagnosis, or treatment of any disease or disorder in humans or animals.

For the Scope of Collaboration, the Parties will work together to research, develop and commercialize Lead Compounds pursuant to this Agreement in the Territory.

License Property
Licensor conducts research and develops and markets pharmaceutical products for the treatment of a variety of disorders, including without limitation products having utility in the treatment of bone disorders, skeletal muscle disorders, cardiac muscle disorders, arthritis, gastrointestinal disorders, obesity, and anti-infectives.

Agrin means the compounds claimed in the United States Patent Application Serial Number 08/644,271 and any continuations, divisionals or continuation-in-parts thereof, and any molecules representing one or more amino acid substitutions, deletions, or additions derived therefrom.

Compound means a chemical entity, which is not Excluded Technology, with research or commercial utility in the Field for methods of research, diagnosis, treatment or prevention of any disease or disorder in humans or animals, and which is conceived and/or reduced to practice by Licensee, or acquired by Licensee from a Third Party with the right to sublicense, before or during the Research Term; or is conceived and/or reduced to practice by Licensor, or acquired by Licensor from a Third Party with the right to sublicense, prior to or during the Research Term.

GPCR means a G-protein coupled receptor.

Field of Use
For this grant portion of the agreement, the Parties agree that Licensor does not grant any rights to the small molecules in the Phosphatase program,  other than those Compounds in the Muscle Field or DDR Field.

Field means the collective areas in which the Parties shall collaborate encompassing the discovery, development, supply and commercialization of products or processes in the Muscle Field, the GPCR Field or the DDR Field.

DDR Field means the discovery, development, supply and commercialization of products or processes that modulate the function of the receptor tyrosine kinases DDR1 and/or DDR2 (or any receptor having at least seventy-five percent (75%) homology with DDR1 or DDR2) whose biological action is primarily due to this modulation.

GPCR Field means the discovery, development, supply and commercialization of products or processes that directly bind and/or modulate the function of the twelve GPCRs.

Muscle Field means the discovery, development, supply and/or commercialization of products (except MuSK and/or Agrin) or processes that diagnose, prevent and/or treat conditions in humans and animals associated with the promotion or protection of skeletal muscle mass or function (including, without limitation, the diagnosis, treatment or prevention of muscle atrophy or sarcopenia).

IPSCIO Record ID: 356267

License Grant
For the Development License, Licensor grants to Janssen an exclusive, worldwide license, with the right to sublicense, under the Licensor Background IP and Licensors rights in the Development Program IP, to Develop and have Developed Licensor Single APIs and Licensed Products in the field, and to make and Manufacture, have made and Manufactured, use, have used, and import Licensor Single APIs and Licensed Products for such purposes.

For the Commercialization License, Licensor grants an exclusive, worldwide license, with the right to sublicense, under the Licensor Background IP and Licensors rights in the Development Program IP, to Commercialize and have Commercialized, offer for sale and sell, and have offered for sale and sold. Licensor Single APls and Licensed Products for use in the Field. and to make. have made. use, have used. and import Licensor Single APls and Licensed Products for such purposes.

This agreement includes a non-exclusive grant back to Licensor from Licensee.

License Property
Licensor possesses certain information, materials, and intellectual property rights relating to certain drug substances in clinical development for treating hepatitis C virus (HCV) infection, including the compound known as ACH-3102, which is an HCV NS5A inhibitor, the compound known as ACH-3422, which is an HCV NS5B inhibitor, and the compound known as sovaprevir, which is an HCV NS3/4A inhibitor.

Licensors Single API means an ACH NS3/4A API, ACH NS5A API, or ACH NS5B API.

The patents include but are not limited to
4-amino-4-oxobutanoyl peptides as inhibitors of HCV Replication, and,
Novel processes for producing sovaprevir.

Field of Use
The Field of use means the prevention, treatment, and/or diagnosis of any and all human disorders or medical conditions, including the treatment of hepatitis C virus (HCV) infection.

IPSCIO Record ID: 211864

License Grant
For the Non-Exclusive Research License to Licensor Base Technology, Licensor grants a non-exclusive, world-wide license under the Base Technology to conduct research and development activities pursuant to the Research Plan, with no right to sublicense.   Licensor also grants the right to sublicense or transfer the rights granted under the Collaboration Technology to Affiliates; and to Third Parties.
License Property
License agreement is for the development of orally bioavailable small-molecule compounds identified through the application of PTC’s proprietary GEMS (Gene Expression Modulation by Small Molecules) technology.

GEMS (Gene Expression Modulation by Small-Molecules) is a novel drug discovery platform technology which enables identification of compounds that target the post-transcriptional regulation of gene expression.

GEMS-UTR (Gene Expression Modulation by Small-Molecules Untranslated Region) is a proprietary screening technology for the identification of small molecules that modulate gene expression by targeting the post-transcriptional control processes that act through the UTRs of mRNA molecules.

The Licensed Product shall mean any Product which incorporates a Collaboration Compound as an active ingredient.  The Collaboration Compound shall mean, on a Target-specific basis, a chemical compound that is synthesized or identified by the Parties, and any metabolites, prodrugs, solvates, including without limitation hydrates, analogs, esters, salts, derivatives, stereoisomers, racemates, tautomers and polymorphs of such chemical compound which are determined to be Active. Collaboration Compound shall include any of a Hit, a Research Compound, a Lead Compound or an IND Candidate.

Field of Use
Field shall mean the prevention, treatment or diagnosis of all diseases or conditions in humans or animals.

This agreement pertains to drug discovery.

IPSCIO Record ID: 303948

License Grant
Licensor assigns all of Licensor’s right, title and interest in the Assigned Patents and Assigned Know-How.

Licensor grants a non- exclusive, revocable, sublicenseable, nontransferable license, under the Licensed Know- How to Research, Develop, Manufacture, have Manufactured, use, keep, sell, offer for sale, import, export and Commercialize the Assigned Compounds and Products in the Field of Use in the Territory during the Term.

This agreement includes an exclusive grant back to Licensor.

License Property
Licensor owns rights to the proprietary compounds identified as VX-222 and VX-497.

VX-222 is an investigational HCV (Hepatitis C Virus) polymerase inhibitor.  Treatment with VX-222 resulted in mean reductions in plasma HCV RNA of greater than 3 log10.

VX-497, or merimepodib, is a drug for autoimmune diseases.

Field of Use
The field of use is the field of anti-infectives and anti-virals and the diagnosis, treatment, or prevention thereof.

VX-222 is for the oral Treatment of Hepatitis C.  VX-497, or merimepodib, is an oral treatment for HCV (Hepatitis C Virus) infection.  This agreement Field does not limit the use to HCV, but does limit the use to Anti-infectives and Anti-virals.

IPSCIO Record ID: 279355

License Grant
License to Commercialize Collaboration Compounds –  Licensor grants to Licensee a worldwide, exclusive license, with the right to sublicense, under the Licensor IP and Licensors interest in the Collaboration IP, to make, have made, use, sell, offer to sell and import Collaboration Compounds, and/or Collaboration Products based on such Collaboration Compounds, for any and all uses and indications in the Licensee Field.

License to Compounds (Other than Collaboration Compounds)  Derived from Licensee Compounds – Licensor grants to Licensee a worldwide, exclusive license, with the right to sublicense, under the Licensor IP and Licensors interest in the Collaboration IP, to make, have made, use, sell, offer to sell and import Collaboration Compounds, and/or Collaboration Products based on such Collaboration Compounds, for any and all uses and indications in the Licensee Field.

License Property
Collaboration Product shall mean a pharmaceutical product containing a Collaboration Compound that is sold by Licensee or Licensor, or their respective Sublicensees or Affiliates.  It is understood that, in the event any Collaboration Compound is sold for therapeutic purposes, such Collaboration Compound shall be deemed a Collaboration Product and shall be subject to milestones and royalties as set forth in this Agreement.

Collaboration Compound shall mean a Licensor Compound or a Non-Exclusive Compound or a compound that is derived, directly or indirectly, from a Licensee Compound, Licensor Compound, or Non-Exclusive Compound; in each case, that modulates the biological activity of a Collaboration Target at a level of potency to be established by the JRC.  A compound shall be deemed to have been derived directly from another compound if it (i) is the result of a chemical modification made to such a compound, (ii) is otherwise obtained from a chemical synthesis program based on one or more such compounds, (iii) is based on proprietary structure-activity data obtained from the testing of one or more such compounds, or (iv) is specifically or generically within the scope of one or more claims of any patent application or patent filed by Licensor or Licensee or their Affiliates to protect any compound in category (i), (ii) or (iii) above.  A compound shall be deemed to have been derived indirectly from another compound if it is the result of a series of iterations of any or all of (i) through (iv) above.  For purposes of clarity, any compound synthesized in the course of the Collaboration and based on a Licensee Compound, Licensor Compound, or Non-Exclusive Compound which is active against a Collaboration Target at the level of potency established by the JRC shall be deemed a Collaboration Compound.  Joint Research Committee or “JRC” shall mean the entity organized to manage the scientific implementation of the Collaboration.

Licensee IP shall mean Licensee Patents and Licensee Know-how.

Collaboration IP shall mean Collaboration Patents and Collaboration Know-how.  Collaboration IP shall not include Licensor IP or Licensee IP.

Licensor IP shall mean Licensor Patents and Licensor Know-how.  Licensor IP shall not include any intellectual property owned or licensed by Licensor or its Affiliates relating to the ECLiPSâ„¢ technology (i.e., the creation or use of encoded combinatorial libraries or any tag and/or marker compounds).

Licensee Patents shall mean all Patents in the Territory Controlled by Licensee or its Affiliates as the effective date, or any other Patent Controlled by Licensee during the Term; in each case, necessary for the discovery, development, manufacture, importation or use of one or more Collaboration Compounds and/or the development, manufacture, use, sale, importation or commercialization of corresponding Collaboration Products.

Licensor Patents shall mean all Patents in the Territory Controlled by Licensor or its Affiliates as the Effective Date, or any other Patent Controlled by Licensor during the Term; in each case, necessary for the discovery, development, manufacture, importation or use of one or more Collaboration Compounds and/or the development, manufacture, use, sale, importation or commercialization of corresponding Collaboration Products.

Collaboration Patents shall mean (i) all patents and patent applications claiming any invention or discovery which was conceived or reduced to practice during the Collaboration Term and in the course of the Collaboration, by employees or agents of Licensee, Licensor or any of their respective Affiliates, either alone or jointly (including, without limitation, the synthesis and composition of matter of any Collaboration Compound, or method of use thereof; and (ii) any divisions, continuations, continuations-in-part, reissues, reexaminations, extensions or other governmental actions which extend any of the subject matter of the patent applications or patents in (i) above, and any substitutions, confirmations, registrations, revalidations, or additions of any of the foregoing, in each case, which is owned or Controlled, in whole or part, by license, assignment or otherwise by Licensor or Licensee during the term of this Agreement; provided, however, that Collaboration Patents shall not include any Licensee Patents or Licensor Patents.

Licensor Compound shall mean any compound brought to the Collaboration by Licensor, which is Controlled by Licensor at or after the Effective Date, and which is proprietary to Licensor by virtue of being within the Licensor IP.

Field of Use
The primary objective of the alliance is to identify active molecules and bring them forward to clinical proof of concept, yielding novel candidates for drug development in various therapeutic areas.

Licensor Field shall mean, with respect to each Collaboration Compound for which Licensor has received approval to develop pursuant, all human and animal disorders and diseases treated by modulation of a Collaboration Target by such Collaboration Compound.

Licensee Field shall mean, with respect to each Collaboration Compound, all human and animal disorders and diseases treated by modulation of a Collaboration Target by such Collaboration Compound.

IPSCIO Record ID: 243454

License Grant
Pursuant to this agreement, Licensee shall solely own all marketing rights to Products, including, not limited to, the exclusive, worldwide, transferable rights to market, sell, have sold, import, export and distribute solely Products.

Licensor will provide all Compounds to Licensee on an exclusive basis, and Licensor is expressly prohibited from providing any and all such Compounds to a Third Party as part of the Licensor Library, without the prior written consent of Licensee.

Licensor grants a nonexclusive, worldwide, transferable and sublicensable right and license to Licensor Technology to the extent that it is necessary for Licensee, to develop, make, have made, use, import, export, offer for sale, have sold and sell Development Compound(s) and/or Product(s).

And, for the research, Licensor grants a worldwide, non-exclusive, non-transferable, non-sublicensable, right and license under the Licensor Technology solely to conduct activities assigned to Licensee under the Research Plan during the term of the Research Collaboration.

License Property
Product shall mean any human diagnostic, human therapeutic and/or human prophylactic product for use within the Field and incorporating a Compound.

Compound shall mean any one or more chemical entity(ies) that is specifically designed by Licensee and/or Licensor in the course of performing or in connection with the Research Plan; or designed by Licensee and/or Licensor, and synthesized by Licensor, in the course of performing or in connection with the Research Plan; or synthesized by Licensor in the course of performing or in connection with the Research Plan; or has been designated as a Development Compound.

LC-MS/ELSD shall mean liquid chromatography mass spectrometry with evaporative light scattering detector.

“Target(s)” shall mean any one or more of (a) the HIV gp120 glycoprotein, including all genetic variants of such glycoprotein, or (b) the HIV gp41 glycoprotein, including all genetic variants of such glycoprotein.

Under the terms of the agreement, the Companies will work to identify small molecule inhibitor compounds against two HIV entry targets, gp41 and gp120. The Companies will collaborate to identify orally active lead compounds and then optimize preclinical candidates.

Field of Use
Field shall mean the discovery, development and commercialization of small chemical molecules for the diagnosis of, or the therapeutic and/or prophylactic treatment of all human conditions and/or diseases.

Collaborative agreement relates to discover and develop small molecule entry inhibitors of the human immunodeficiency virus (HIV).

IPSCIO Record ID: 273462

License Grant
Licensor grants a worldwide, exclusive, and sublicensable right and license to practice the Licensor Technology and all of Licensors rights in Collaboration Patent Rights to make. have made. use. import, promote, market,  or sell Licensed Products in the Licensed Field.

Licensor grants a worldwide, exclusive or non-exclusive, as the case may be, and sublicenseable  right and license to practice the Third Party Technology to make, have made, use, import, promote, market, distribute or sell Licensed Products in the Licensed Field.

For the Grant of License to Joint Collaboration Patent Rights Outside the Licensed Field, Licensor grants a worldwide, non-exclusive, and sublicenseable right and license to practice Licensors rights in Joint Collaboration Patent Rights to make, have made, import, promote, market, distribute or sell products or processes outside the Licensed Field.

License Property
The Patent Rights and Know-How are pertaining to the PADRE® Technology.

Licensed Product shall mean a therapeutic or prophylactic vaccine the manufacture. use or sale of which, but for any license granted to Licensee herein, would infringe a Valid Claim of one or more Licensor Patent Rights or one or more Collaboration Patent Rights, or was developed or manufactured using Licensor Know-How.

PADRE® Technology shall mean a family of immunostimulatory molecules which when combined with cytotoxic T cell epitopes increase the magnitude and duration of the immune response.

Field of Use
Licensed Field shall mean the research, development and commercialization of Licensed Products for treating or preventing diseases associated with the following viruses HPV. HBV and HCV.  HBV shall mean Hepatitis B Virus.  HCV shall mean Hepatitis C Virus.  HPV shall mean Human Papilloma Virus.   First HPV Indication shall mean treatment or prevention of cervical dysplasias and neoplasia.

IPSCIO Record ID: 279318

License Grant
For the exclusive license, Licensor grants to the Licensee of Japan an exclusive right and license in the Territory under Licensors interest in the Collaboration Patent and the Collaboration Know-How, with a right to sublicense, to develop, make, have made, use, offer for sale and/or sell, import and export any Active Compound, Active Claimed Compound and/or Derivative Compound, and, also with a right to sublicense, to develop, make, have made, use, import and export, offer for sale and/or sell any Collaboration Product or Product.

For the Non-Exclusive Licenses for
—  The Collaboration Technology, Licensor grants to a non-exclusive, sublicensable license in the Territory under Licensors interest in the Collaboration Patent and the Collaboration Know-How, to develop, make, have made, use, offer to sell, sell, import and export any Inactive Compound or Claimed Compound, other than Active Claimed Compounds, and upon Licensees discovery that a particular Inactive Compound or such Claimed Compound is active against a particular target, the right to negotiate to obtain the exclusive rights to such Inactive Compound or Claimed Compound, in each case in the Territory.
—  The Pre-existing Licensor Patents, In the event that the development, making, having made, use, offer for sale, sale, import and export by Licensee of any Active Compound, Inactive Compound, Active Claimed Compound, Claimed Compound or Derivative Compound, any Collaboration Product, Product or any product containing an Inactive Compound, a Claimed Compound or Derivative Compound would infringe during the term of the Agreement a claim of Pre-existing Licensor Patent, Licensor grants to the extent Licensor is legally able to do so, a non-exclusive, sublicensable, license in the Territory under such Pre-existing Licensor Patent for those purposes, and,
— The Inactive Compounds and Claimed Compounds, with respect to an Inactive Compound or a Claimed Compound, at least 90 days prior to Licensor entering into material and substantial negotiations to grant to a Third Party any rights to such Inactive Compound or Claimed Compound, Licensor agrees to notify Licensee in writing, together with a description of the chemical entity that would be the subject of such negotiations. Within 30 days after receipt from Licensor of such notice, Licensee shall notify Licensor whether or not it desires to discuss terms and conditions under which Licensor would grant exclusive rights to such Inactive or Claimed Compound to Licensee.

License Property
Licensor has expertise and proprietary technology for the discovery, generation, optimization and preclinical testing of small molecule clinical candidates from drug discovery programs.
Field of Use
The Field means the discovery, development and commercialization of small molecules for the diagnosis or therapeutic or prophylactic treatment of diseases and conditions, wherein the primary mechanism of action of such small molecules is to modulate the activity of a Collaboration Target.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.